Fig. 1 · Structure

Documents & Downloads

Gilteritinib (ASP2215)

Cat. No. A14411 CAS 1254053-43-4

FLT3/Axl inhibitor

Gilteritinib is a potent FLT3/AXL inhibitor, which showed potent antileukemic activity against AML with either or both FLT3-ITD and FLT3-D835 mutations.

In Stock

Publications for Gilteritinib

1 publication citing this product

  1. Mohammad Azhar, .et al. , Blood Adv, 2022, Aug 31 PMID: 36044389

Free Aliquoting for Your Order

Tell us your preferred amount per vial. We’ll confirm the options.

Biological Activity

Bioactivity / Mechanism

Gilteritinib (ASP2215) inhibited FLT3 and AXL in cell-free kinase assays. In the reported hemifumarate study, geometric mean IC50 values were 0.29 nM for FLT3 and 0.73 nM for AXL, compared with 230 nM for c-KIT (three experiments). These biochemical results do not establish the contribution of AXL inhibition to antileukemic efficacy. [1]

Literature-reported observations and conditions; not Adooq-tested protocols or general treatment recommendations.

Cellular Effect

Cell Line Activity Value Description Reference
BaF3 IC50 0.7 nM Antiproliferative activity against mouse BaF3 FLT3-D835 cells assessed as reduction in cell viability measured after 72 hrs by MTS assay [PMID: 32659083]
BaF3 IC50 1.6 nM Antiproliferative activity against mouse BaF3 FLT3-ITD cells assessed as reduction in cell viability measured after 72 hrs by MTS assay [PMID: 32659083]
BaF3 GI50 1.6 nM Growth inhibition of mouse BaF3 cells transfected with FLT3-D835Y assessed as inhibition of cell growth measured after 48 hrs by MTT assay [PMID: 35923716]
BaF3 GI50 1.8 nM Growth inhibition of mouse BaF3 cells transfected with FLT3-ITD assessed as inhibition of cell growth measured after 48 hrs by MTT assay [PMID: 35923716]
BaF3 IC50 1.8 nM Antiproliferative activity against mouse BaF3 cells expressing FLT3-ITD by cell-titre glo luminescent cell viability assay [PMID: 33719439]
BaF3 GI50 2 nM Antiproliferative activity against mouse Ba/F3 cells harbouring FLT3 D835Y mutant assessed as growth inhibition measured after 72 hrs by CellTiter-Glo assay [PMID: 34324343]
BaF3 IC50 2.1 nM Antiproliferative activity against mouse BaF3 cells expressing FLT3-ITD-D835Y mutant by cell-titre glo luminescent cell viability assay [PMID: 33719439]
BaF3 GI50 258.6 nM Antiproliferative activity against mouse Ba/F3 cells harbouring FLT3 ITD F691I mutant assessed as growth inhibition measured after 72 hrs by CellTiter-Glo assay [PMID: 34324343]
BaF3 GI50 5 nM Antiproliferative activity against mouse Ba/F3 cells harbouring FLT3 ITD D835Y mutant assessed as growth inhibition measured after 72 hrs by CellTiter-Glo assay [PMID: 34324343]
BaF3 IC50 7.6 nM Antiproliferative activity against mouse BaF3/TEL-AXL cells incubated for 72 hrs by SRB or CCK8 assay [PMID: 33733758]
BaF3 GI50 82.8 nM Antiproliferative activity against mouse Ba/F3 cells harbouring FLT3 ITD F691L mutant assessed as growth inhibition measured after 72 hrs by CellTiter-Glo assay [PMID: 34324343]
HepG2 GI50 2.2 μM Antiproliferative activity against human HepG2 cells assessed as cell growth inhibition by WST assay [PMID: 32272419]
K562 GI50 1.006 μM Antiproliferative activity against human K562 cells assessed as cell growth inhibition by WST assay [PMID: 32272419]
MOLM-14 IC50 1.8 nM Antiproliferative activity against human MOLM-14 cells expressing FLT3-ITD mutant assessed as inhibition of cell proliferation measured after 72 hrs by celltiter-glo luminescent cell viability assay [PMID: 32659083]
MOLM-14 GI50 1.91 nM Antiproliferative activity against human MOLM14 cells harboring ITD/D835Y mutant assessed as cell growth inhibition by MTT assay [PMID: 32272419]
MOLM-14 GI50 3.29 nM Antiproliferative activity against human MOLM14 cells harboring ITD mutant assessed as cell growth inhibition by MTT assay [PMID: 32272419]
MOLM-14 GI50 4.94 nM Antiproliferative activity against wild type human MOLM14 cells assessed as cell growth inhibition by MTT assay [PMID: 32272419]
MOLM-14 GI50 5.24 nM Antiproliferative activity against human MOLM14 cells harboring ITD/F691L mutant assessed as cell growth inhibition by MTT assay [PMID: 32272419]
MV4-11 GI50 0.0009 μM Antiproliferative activity against human MV4-11 cells assessed as cell growth inhibition by Celltiter-Glo luminescent assay [PMID: 32272419]

19 records · Scroll to view more

Gilteritinib (ASP2215) Research Summary

This section summarizes 3 in vitro studies and 1 in vivo study of Gilteritinib (ASP2215) from 2 published references. In vitro models include cell-free tyrosine kinase assays; mononuclear cells from normal human donor bone marrow.

Gilteritinib (ASP2215) In Vitro Studies

In cellular immunoblot assays, gilteritinib inhibited FLT3 phosphorylation with IC50 values of 5 nM in wild-type FLT3-expressing SEMK2 cells and 1.8 nM in FLT3-ITD-expressing Molm14 cells. The Ba/F3 FLT3-ITD/F691L model had a higher IC50 of 12.2 nM, indicating reduced potency in that model. These values measure receptor phosphorylation, not cell viability. [2]

In normal-donor bone marrow colony assays, gilteritinib preserved CFU-GM and BFU-E recovery more strongly than quizartinib over the displayed 0–200 nM range, with some reduction at higher concentrations. This ex vivo result does not establish freedom from clinical myelosuppression. [2]

Cell-free tyrosine kinase inhibition

Biochemical assay · Cell-free tyrosine kinase assays [1]

FLT3 and AXL inhibition was stronger than c-KIT inhibition, with activity also detected against LTK and EML4-ALK. These biochemical values do not establish cellular selectivity or the contribution of AXL to antitumor effects.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
FLT3 kinase activityGeometric mean IC50 (95% CI) 0.29 (0.26–0.32) nM[1]
AXL kinase activityGeometric mean IC50 (95% CI) 0.73 (0.51–1.0) nM[1]
LTK kinase activityGeometric mean IC50 (95% CI) 0.35 (0.29–0.43) nM[1]
EML4-ALK kinase activityGeometric mean IC50 (95% CI) 1.2 (0.68–2.0) nM[1]
c-KIT kinase activityGeometric mean IC50 (95% CI) 230 (190–280) nM[1]

Literature-Reported Treatment Conditions

Treatment concentration
Concentration-response assays; initial 78-kinase screen at 1 and 5 nM.
Method
Cell-free kinase inhibition; three individual IC50 experiments per kinase.
Vehicle
DMSO for in vitro compounds (shared materials).
Reported limits
Exact concentration series and incubation duration are not specified in the acquired main-text kinase methods. No cellular treatment exposure inferred.
Methods and source locations

Compound reported in the paper: Gilteritinib (ASP2215); Compound label in the paper: Gilteritinib hemifumarate

Evidence for the named compound in the stated model and reported form; does not validate Adooq lots or establish free-base/salt equivalence.

Materials and methods: Compounds and Kinase inhibitory assays; Results: Gilteritinib inhibitory activity; Table 1

FLT3 kinase activity: TK-ELISA/off-chip mobility shift assay; HTRF KinEASE-TK for EML4-ALK. ATP approximately at each kinase Km. — Table 1 (geometric mean IC50 and 95% CI; 3 experiments)

AXL kinase activity: TK-ELISA/off-chip mobility shift assay; HTRF KinEASE-TK for EML4-ALK. ATP approximately at each kinase Km. — Table 1 (geometric mean IC50 and 95% CI; 3 experiments)

LTK kinase activity: TK-ELISA/off-chip mobility shift assay; HTRF KinEASE-TK for EML4-ALK. ATP approximately at each kinase Km. — Table 1 (geometric mean IC50 and 95% CI; 3 experiments)

EML4-ALK kinase activity: TK-ELISA/off-chip mobility shift assay; HTRF KinEASE-TK for EML4-ALK. ATP approximately at each kinase Km. — Table 1 (geometric mean IC50 and 95% CI; 3 experiments)

c-KIT kinase activity: TK-ELISA/off-chip mobility shift assay; HTRF KinEASE-TK for EML4-ALK. ATP approximately at each kinase Km. — Table 1 (geometric mean IC50 and 95% CI; 3 experiments)

Cellular FLT3 phosphorylation across receptor subtypes

Cell-based study · SEMK2 wild-type FLT3, Molm14 FLT3-ITD, and Ba/F3 cells bearing defined FLT3 variants [2]

Gilteritinib inhibited FLT3 phosphorylation at low nanomolar concentrations in these cellular models. The ITD/F691L model required a higher concentration than the other listed variants; phosphorylation IC50 is distinct from cell-viability IC50.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
SEMK2, wild-type FLT3 phosphorylationIC50 5 nM[2]
Molm14, FLT3-ITD phosphorylationIC50 1.8 nM[2]
Ba/F3, FLT3-D835Y phosphorylationIC50 1.4 nM[2]
Ba/F3, FLT3-D835H phosphorylationIC50 2 nM[2]
Ba/F3, FLT3-D835V phosphorylationIC50 0.7 nM[2]
Ba/F3, FLT3-ITD/F691L phosphorylationIC50 12.2 nM[2]

Literature-Reported Treatment Conditions

Treatment concentration
Increasing ASP2215 concentrations; IC50 values are endpoints, not administered doses.
Exposure duration
1 hour
Method
Cell incubation in RPMI/10% FBS, followed by phospho-/total-FLT3 immunoprecipitation/immunoblot and densitometry.
Reported limits
Exact titration range, solvent and replicate count not established from acquired main text; supplemental methods not retrieved.
Methods and source locations

Compound reported in the paper: Gilteritinib (ASP2215); Compound label in the paper: Gilteritinib / ASP2215; salt form not established from acquired main text

Evidence for the named compound in the stated model and reported form; does not validate Adooq lots or establish free-base/salt equivalence.

Main text receptor-inhibition paragraph; Figure 1A and caption

SEMK2, wild-type FLT3 phosphorylation: Phospho- and total-FLT3 immunoprecipitation/immunoblot with densitometry; each IC50 calculated from multiple experiments (exact n not supplied in caption). — Figure 1A table and caption; main text receptor-inhibition paragraph

Molm14, FLT3-ITD phosphorylation: Phospho- and total-FLT3 immunoprecipitation/immunoblot with densitometry; each IC50 calculated from multiple experiments (exact n not supplied in caption). — Figure 1A table and caption; main text receptor-inhibition paragraph

Ba/F3, FLT3-D835Y phosphorylation: Phospho- and total-FLT3 immunoprecipitation/immunoblot with densitometry; each IC50 calculated from multiple experiments (exact n not supplied in caption). — Figure 1A table and caption; main text receptor-inhibition paragraph

Ba/F3, FLT3-D835H phosphorylation: Phospho- and total-FLT3 immunoprecipitation/immunoblot with densitometry; each IC50 calculated from multiple experiments (exact n not supplied in caption). — Figure 1A table and caption; main text receptor-inhibition paragraph

Ba/F3, FLT3-D835V phosphorylation: Phospho- and total-FLT3 immunoprecipitation/immunoblot with densitometry; each IC50 calculated from multiple experiments (exact n not supplied in caption). — Figure 1A table and caption; main text receptor-inhibition paragraph

Ba/F3, FLT3-ITD/F691L phosphorylation: Phospho- and total-FLT3 immunoprecipitation/immunoblot with densitometry; each IC50 calculated from multiple experiments (exact n not supplied in caption). — Figure 1A table and caption; main text receptor-inhibition paragraph

Normal-donor hematopoietic colony formation

Cell-based study · Mononuclear cells from normal human donor bone marrow [2]

Relative to the zero-drug baseline, gilteritinib preserved colony recovery more strongly than quizartinib over the displayed concentration range. Recovery was not completely preserved at the highest concentrations. This ex vivo observation does not demonstrate clinical absence of myelosuppression.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
CFU-GM and BFU-E clonogenic recoveryClonogenic recovery (% of baseline) Qualitatively greater preservation with gilteritinib than quizartinib; some reduction at 100–200 nM. Caption: n = 3.[2]

Literature-Reported Treatment Conditions

Treatment concentration
Gilteritinib or quizartinib: 0, 10, 20, 50, 100 and 200 nM (Fig. 2B).
Exposure duration
10–12 days
Method
Normal-donor bone marrow mononuclear cells plated at 10^5 cells/mL in MethoCult; CFU-GM and BFU-E counted.
Co-treatment
None; gilteritinib and quizartinib tested separately.
Reported limits
Solvent, donor count and precise n semantics not established in the acquired caption/main text; supplemental methods not retrieved.
Methods and source locations

Compound reported in the paper: Gilteritinib (ASP2215); Compound label in the paper: Gilteritinib / ASP2215; salt form not established from acquired main text

Evidence for the named compound in the stated model and reported form; does not validate Adooq lots or establish free-base/salt equivalence.

Main text c-Kit/hematopoiesis paragraph; Figure 2B and caption

CFU-GM and BFU-E clonogenic recovery: Colony counts after 10–12 days; Figure 2B viewed. No exact percentages inferred from bars; caption does not define whether n = 3 denotes donors or other replicates. — Figure 2B, caption and adjacent main-text c-Kit paragraph

Gilteritinib (ASP2215) In Vivo Studies

In a female NOD-SCID MV4–11-luc bone marrow AML model, oral gilteritinib hemifumarate at the reported 30 mg/kg once daily for 56 days reduced leukemic bioluminescence and prolonged survival versus vehicle (10 mice/group). All treated mice survived to day 168; vehicle median survival was 61.5 days. The study did not establish whether AXL inhibition contributed to this response. [1]

Leukemic burden and survival in an intra-bone marrow AML model

Animal study · Female NOD-SCID mice bearing MV4–11-luc AML cells in bone marrow; n = 10 mice/group [1]

Once-daily oral gilteritinib reduced bioluminescent leukemic burden and prolonged survival versus vehicle. All treated mice survived to day 168. This immunodeficient cell-line model does not identify the contribution of AXL or establish human efficacy.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Survival through day 168Survival All gilteritinib-treated mice survived to day 168; vehicle median survival 61.5 days; P < 0.001 (log-rank test). n = 10 mice/group.[1]
Whole-body bioluminescent leukemic burdenBioluminescence Reduced versus vehicle at day 42; P < 0.001 (Student’s t-test); data mean ± SEM, n = 10 mice/group.[1]

Conditions shared by the study groups

Route
Oral
Frequency
Once daily
Treatment course
Day 15 to day 70 (56 days)
Vehicle
0.5% methylcellulose
Study groups and reported outcomes
Group / doseComparatorObserved resultReference
Gilteritinib 30 mg/kg
30 mg/kg
Vehicle control, n = 10 mice/groupLower bioluminescent burden and all treated mice alive at day 168; vehicle median survival 61.5 days.[1]
Gilteritinib 30 mg/kg
Model: Female NOD-SCID mice bearing MV4–11-luc AML cells in bone marrow; n = 10 mice/group
Reported limits: Reported hemifumarate material; free-base-equivalent dose not established.
Methods and source locations

Compound reported in the paper: Gilteritinib (ASP2215); Compound label in the paper: Gilteritinib hemifumarate

Evidence for the named compound in the stated model and reported form; does not validate Adooq lots or establish free-base/salt equivalence.

Methods: Compounds, IBMT model and Statistical analyses; Results: Gilteritinib prolongs survival; Figure 5a-c and caption

Survival through day 168: Daily survival monitoring through day 168; Kaplan–Meier analysis. — Results: Gilteritinib prolongs survival; Figure 5c and caption

Whole-body bioluminescent leukemic burden: Whole-body imaging. Direction checked against Fig. 5a-b; no exact curve-derived values extracted. — Figure 5a-b and caption; IBMT methods

Gilteritinib 30 mg/kg · Methods: Compounds, IBMT model and Statistical analyses; Results: Gilteritinib prolongs survival; Figure 5a-c and caption

Specifications

Manufacturer Adooq Bioscience
Actions Inhibitor
CAS Number 1254053-43-4
Applications FLT3/Axl inhibitor
Formula C29H44N8O3
Molecular Weight 552.71
Synonyms ASP2215
SMILES
CCC1=NC(=C(N=C1NC2CCOCC2)NC3=CC(=C(C=C3)N4CCC(CC4)N5CCN(CC5)C)OC)C(=O)N

Storage & Solubility

In Vitro Solubility

Reported Solubility

SolventReported Solubility
DMSO 90 mg/mL (162.83 mM)
Water Insoluble
Ethanol 77 mg/mL

Preparing Stock Solutions

Stock preparation is unavailable for this product molecular weight.

Calculated stock concentrations do not establish solvent solubility. Refer to the reported solubility data for experimental guidance.

Storage

Store powder at -20°C, keep desiccated.
In powder form, the chemical is stable for 36 months.
In solution, store at -20°C and use within 1 month to prevent loss of potency. Aliquot to avoid multiple freeze/thaw cycles.

Gilteritinib (ASP2215) Research References

  1. [1] Masamichi Mori, Naoki Kaneko, Yoko Ueno, et al. Gilteritinib, a FLT3/AXL inhibitor, shows antileukemic activity in mouse models of FLT3 mutated acute myeloid leukemia Invest New Drugs (2017). PMID: 28516360 DOI: 10.1007/s10637-017-0470-z Source material
  2. [2] Lauren Y Lee, Daniela Hernandez, Trivikram Rajkhowa, et al. Preclinical studies of gilteritinib, a next-generation FLT3 inhibitor Blood (2017). PMID: 27908881 DOI: 10.1182/blood-2016-10-745133 Source material

Publications

1 publication citing this product

  1. Mohammad Azhar, .et al. , Blood Adv, 2022, Aug 31 PMID: 36044389

Added to your cart

View Cart Checkout
Loading...